Source: www.lne.es New drugs are responsible for 73% of the prolongation of life expectancy in developed countries and have managed to solve more and more diseases. […]

Source: www.lavozdegalicia.es The sector has registered an investment in research and development of 1,211 million euros in 2019, 5.2% more than the previous year In these […]

Source: www.noticias.juridicas.com Royal Decree 957/2020, of November 3, establishes the conditions that must be met to proceed with the evaluation, performance and monitoring of observational studies […]

New meeting of the Farma-Biotech program, which brings start-ups and research groups into contact with national and international pharmaceutical companies to promote preclinical research and facilitate […]

Pharmaceutical companies are working to ensure seamless access to medicines ahead of the UK’s exit from the EU, due in January Farmaindustria and the British Embassy […]

So, in an exercise of transparency, anyone can have access to this data Carmen Montoto, Takeda Medical Director in Spain Source: www.redaccionmedica.com As part of its […]

In the workshop “Digital challenges in the management of clinical trials”, organized by Farmaindustria, its attendees have shown their commitment to digitization to help Spain consolidate […]

The objective of this meeting has been to present the latest advances in the area of Oncology with experts of national and international origin and to […]

Nine out of ten women diagnosed in Spain survive to 5 years The development of more precise, effective treatments with fewer side effects, together with the […]

  Source: www.redaccionmedica.com María Blasco recalls that investment in science “is not even at the levels prior to 2010” Scientists gathered at the meeting ‘A new […]

A Spanish study “opens a door in a global therapeutic approach” that would allow more patients to be cured Source: www.redaccionmedica.com The survival prospects of patients […]

Even in the harshest months of the pandemic, pharmaceutical companies have continued to promote studies to admit patients, when it was the only therapeutic alternative for […]